Ketamine Infusions Effective as Super-Refractory Status Epilepticus Treatment
Ketamine infusion significantly decreased seizure burden within 24 hours in patients with super-refractory status epilepticus.
Ketamine infusion significantly decreased seizure burden within 24 hours in patients with super-refractory status epilepticus.
During COVID-19, clinicians will be challenged by a lack of ICU resources and ventilators to manage patients with status epilepticus.
Individuals with vs without status epilepticus were found to have a greater prevalence of cardiovascular risk factors and a higher risk of developing cardiovascular diseases.
Results suggest that levetiracetam could be considered as an alternative treatment to phenytoin for second-line management of pediatric convulsive status epilepticus.
Investigators examined various scoring systems to predict recovery to premorbid neurological and functional status in critically ill patients with status epilepticus.
Researchers sought to determine whether the Salzburg Consensus Criteria yielded similar diagnostic results by an inexperienced EEG reader compared with an experienced EEG reader not using the SCC.
Researchers used readily available clinical parameters to determine risk for prolonged status epilepticus at seizure onset, and to predict which patients they anticipated might experience a full recovery.
Aggressive and prolonged treatment of refractory status epilepticus may be justified in patients with cardiac arrest with favorable multimodal prognostic indicators.
There are considerations for treating these seizures as part of the overall goals of palliative care, which include the family’s experience.
The NDA for IM/IV Captisol-Enabled Fosphenytoin has been accepted for review and given a Prescription Drug Fee User Act date, by the FDA.